CTLA4 and neoplasm: In the anti-CTLA-4/PD-1/PD-L1 GEO cohort (GSE91061 and GSE135222), higher DMS in tumor patients was associated with a stronger immune response and higher therapeutic benefits (Figures 6H, I).